Alynlam’s PH1 Therapy Wins Approval in Europe

Alynlam Pharmaceuticals has received marketing authorization in Europe for Oxlumo (lumasiran) as a treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare orphan disease that can lead to renal failure.

Oxlumo is an RNA interference drug meant to halt production of oxalate, a disease-causing toxin that leads to PH1.

Alnylam has also submitted a New Drug Application to the FDA and has received a priority review with a target decision date of Dec. 3.